pharmaphorum

NOVEMBER 16, 2022

Biologic treatments also fit into the general trend across the industry – as it becomes increasingly difficult to find new small molecule treatments that offer benefits to broad patient populations, new therapies are more likely to focus on smaller groups through targeted treatment. However, with a price tag of €1.58 At more than $2.1

131

131

pharmaphorum

AUGUST 28, 2020

Prof Brownstein, who is also chief innovation officer at Boston Children’s Hospital, said: “COVID-19 has put a real focus on the inadequacies of public health. We are ingesting hundreds of thousands of pieces of information daily and we tag that information across locations, disease types, species, and case counts. Data inadequacies.

Hospitals 72

Hospitals 72

pharmaphorum

NOVEMBER 19, 2021

Most countries have purchased their vaccines for the next year or two so where is the opportunity for Sanofi and the like. The market potential for any vaccine currently in trials is lower because the only markets really are the developing countries, which can’t pay the same prices.”. The Kremlin has denied the allegations.

Vaccines 137

Vaccines Communication 137

European Pharmaceutical Review

JULY 11, 2022

“We are delighted to be working with CEPI to further this nanoparticle technology with the goal of producing efficacious, low-cost, infrastructure-independent vaccine that will be accessible to low- and middle-income countries.” . How the novel coronavirus vaccine works. 2 is the virus that causes COVID-19.). The novel vaccine?is

Vaccines 90

Vaccines Immunization 90

Pharmaceutical Technology

JANUARY 27, 2023

Over the last few years, as price tags for drugs have continuously increased, the popularity of risk sharing agreements has been increasing at a rate of 24% annual average growth. In 2022, the number of risk sharing agreements peaked with 144 agreements being made in the pharmaceutical industry. However, obstacles still remain.

Documentation 52

Documentation Immunization Pharmaceutical Companies Pharmaceutical Companies 52

pharmaphorum

SEPTEMBER 30, 2022

This new method of data and Component Management enables regulatory review teams to focus on assessing the data instead of the document – a move that promises to deliver positive long-term results. Reasons for the shift. Aside from the increasing volumes of data, submission teams have other reasons for moving to component management.

Documentation 52

Documentation Pharmaceutical Companies Pharmaceutical Companies 52

Viseven

SEPTEMBER 14, 2023

For instance, depending on sources in tariff-affected countries can substantially increase a pharma company’s operational expenses. Climate change is another factor, potentially disrupting supplies and contributing to hefty price tags. The range of functionalities within e-procurement platforms notably varies.

Packaging 52

Packaging Pharmaceutical Companies Pharmaceutical Companies Pharmacy Procurement 52

The Physician Pharmacist

SEPTEMBER 14, 2023

nathan gartland Yeah, 100% agree with that, you know, folk for any one interested in you know, pursuing medicine focus on the MCAT. That is something I feel like at least in my medical education that's been overlooked to some extent, because we focus so heavily on diagnose diagnostics. nathan gartland I think it's funny too.

Medical Schools 52

Medical Schools Hospitals Communication Patient Care 52

Pharma Marketing Network

JUNE 8, 2020

I mean, you know, there has obviously been a lot of breakthrough biologics and different therapeutics like around cancers and things like that, that have high price tags because maybe they don’t have as big a market as you know, something’s wrong, you know blood pressure medication. So yeah, there is plenty to talk about there.

Health and Personal Care Stores 40

Health and Personal Care Stores Hospitals Mayo Clinic Specialty Pharmacies 40